Edition:
India

Imprimis Pharmaceuticals Inc (IMMY.OQ)

IMMY.OQ on NASDAQ Stock Exchange Capital Market

3.10USD
13 Aug 2018
Change (% chg)

-- (--)
Prev Close
$3.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
21,063
52-wk High
$3.38
52-wk Low
$1.35

Latest Key Developments (Source: Significant Developments)

Imprimis Pharmaceuticals Reports Q2 EPS $0.12
Tuesday, 7 Aug 2018 

Aug 6 (Reuters) - Imprimis Pharmaceuticals Inc ::IMPRIMIS PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2018 RESULTS.Q2 REVENUE ROSE 51 PERCENT TO $10.4 MILLION.QTRLY NET INCOME PER COMMON SHARE $0.12.  Full Article

Imprimis Pharmaceuticals Issued Composition Patent For Non-Opioid Conscious Sedation Formulation
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Imprimis Pharmaceuticals Inc ::IMPRIMIS PHARMACEUTICALS ISSUED COMPOSITION PATENT FOR NON-OPIOID CONSCIOUS SEDATION FORMULATION.IMPRIMIS PHARMACEUTICALS INC - ‍SECURED A PATENT COVERING COMPANY'S MKO MELT COMPOUNDED FORMULATION​.  Full Article

Imprimis Pharmaceuticals Q3 loss per share $‍0.28​
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Imprimis Pharmaceuticals Inc :Imprimis Pharmaceuticals announces third quarter 2017 results.Q3 revenue rose 34 percent to $6.5 million.Imprimis Pharmaceuticals inc qtrly loss per share $‍0.28​.  Full Article

Imprimis Pharmaceuticals implemented an expense reduction program
Monday, 26 Sep 2016 

Imprimis Pharmaceuticals Inc : Co implemented an expense reduction program . Has ceased operations at its Texas facility and implemented an 8% reduction in total headcount . Exploring alternatives for use of Texas facility, estimates will incur total restructuring costs of about $0.6 million under plan .Actions are expected to streamline Imprimis' operations and reduce expected cash based expenses by nearly $3 million annually.  Full Article